Large-vessel vasculitis associated with PEGylated granulocyte-colony stimulating factor

Neth J Med. 2019 Aug;77(6):224-226.

Abstract

A 71-year-old female with advanced endometrial cancer was treated with pegfilgrastim. She developed a fever within seven days, and contrast-enhanced computed tomography scans repeated within three days revealed rapidly progressive thickening of the aortic wall. When clinicians administer PEGylated granulocyte-colony stimulating factor (G-CSF) to cancer patients, drug-associated vasculitis should be suspected. This report discusses the manifestation of G-CSF-associated large-vessel vasculitis (LVV).

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aorta, Thoracic / diagnostic imaging*
  • Endometrial Neoplasms* / pathology
  • Endometrial Neoplasms* / therapy
  • Female
  • Filgrastim* / administration & dosage
  • Filgrastim* / adverse effects
  • Giant Cell Arteritis* / diagnosis
  • Giant Cell Arteritis* / etiology
  • Giant Cell Arteritis* / therapy
  • Glucocorticoids / administration & dosage
  • Hematologic Agents / administration & dosage
  • Hematologic Agents / adverse effects
  • Humans
  • Neoplasm Staging
  • Neutropenia* / chemically induced
  • Neutropenia* / diagnosis
  • Neutropenia* / drug therapy
  • Polyethylene Glycols* / administration & dosage
  • Polyethylene Glycols* / adverse effects
  • Positron Emission Tomography Computed Tomography / methods
  • Prednisolone / administration & dosage*
  • Radiographic Image Enhancement / methods
  • Treatment Outcome

Substances

  • Glucocorticoids
  • Hematologic Agents
  • pegfilgrastim
  • Polyethylene Glycols
  • Prednisolone
  • Filgrastim